CLINICAL_TRIALS ClinicalTrials.gov record update

CD45 and Alemtuzumab Monoclonal Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Severe Combined Immunodeficiency Disease (SCID) And Other Primary Immunodeficiency Disorders

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00579137
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:28.744951+00:00
Published At: 2013-07-02T00:00:00+00:00
Record Updated At: 2013-07-02
Results Posted At: 2013-07-02
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Severe Combined Immunodeficiency Disease", "Severe Primary Immunodeficiency Disorder", "Undefined T Cell Deficiency Disorder", "Wiskott-Aldrick Syndrome"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2013-07-02"
protocolSection.identificationModule.nctId: "NCT00579137"
protocolSection.identificationModule.officialTitle: "CD45 and Alemtuzumab Monoclonal Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Severe Combined Immunodeficiency Disease (SCID) And Other Primary Immunodeficiency Disorders"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2013-07-02"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.